Mesoblast CEO on FDA Approval, Development Pipeline

Dr. Silviu Itescu, CEO of the biotech company Mesoblast (MESO), joins Market On Close. The company is developing therapeutics using stem cells to target severe inflammatory conditions, including pediatric conditions. He discusses Mesoblast’s recent FDA approval for a cell therapy that is the first of its type, and its potential uses in bone marrow transplant patients.

Market On Close

03 Jan 2025

SHARE

Schwab Network's Newsletters

Daily insights for every investor

ON AIR
6:00 pm
The Wrap
replay
12:00 am
The Wrap
REPLAY
12:30 am
Market On Close
REPLAY
2:00 am
Trading 360
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
ON AIR
6:00 pm
The Wrap
REPLAY
7:30 pm
Market Overtime
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market On Close
REPLAY
10:00 pm
Trading 360
REPLAY
11:00 pm
The Wrap
REPLAY